Cash and Short Term Investments (Quarterly) Chart

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 489.18M
March 31, 2026 264.68M
December 31, 2025 322.80M
September 30, 2025 254.53M
June 30, 2025 319.54M
March 31, 2025 322.24M
December 31, 2024 370.70M
September 30, 2024 277.44M
June 30, 2024 325.40M
March 31, 2024 441.04M
December 31, 2023 566.85M
September 30, 2023 634.64M
June 30, 2023 491.34M
March 31, 2023 561.51M
December 31, 2022 450.24M
September 30, 2022 506.33M
June 30, 2022 553.17M
March 31, 2022 603.39M
December 31, 2021 552.88M
September 30, 2021 551.18M
June 30, 2021 522.79M
March 31, 2021 520.87M
December 31, 2020 361.59M
September 30, 2020 456.27M
June 30, 2020 457.38M
Date Value
March 31, 2020 356.46M
December 31, 2019 398.52M
September 30, 2019 407.02M
June 30, 2019 425.90M
March 31, 2019 447.65M
December 31, 2018 471.54M
September 30, 2018 478.81M
June 30, 2018 255.69M
March 31, 2018 264.06M
December 31, 2017 300.63M
September 30, 2017 303.87M
June 30, 2017 295.98M
March 31, 2017 248.16M
December 31, 2016 255.87M
September 30, 2016 274.30M
June 30, 2016 221.51M
March 31, 2016 222.34M
December 31, 2015 229.60M
September 30, 2015 235.28M
June 30, 2015 133.61M
March 31, 2015 126.33M
December 31, 2014 27.76M
September 30, 2014 37.79M
June 30, 2014 43.44M
March 31, 2014 5.041M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
TG Therapeutics, Inc. 552.25M
BioMarin Pharmaceutical, Inc. 874.00M
Vertex Pharmaceuticals, Inc. 7.863B
Viridian Therapeutics, Inc. 981.53M
Krystal Biotech, Inc. 845.63M